Vyhledat

60 Result(s)
Seřadit podle

commitments to sustainable development

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Boehringer Ingelheim partners with PetMedix

Boehringer Ingelheim partners with PetMedix

Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
collaboration-kings-college-london

collaboration-kings-college-london

Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
university-of-medical-excellence-harvard

university-of-medical-excellence-harvard

A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
environmental sustainability commitments

environmental sustainability commitments

On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Clinical-phase2-trials-NASH-and-obesity

Clinical-phase2-trials-NASH-and-obesity

Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
PatientView survey

PatientView survey

Boehringer Ingelheim among top ten most “patient-centric” pharma companies
cystic fibrosis phase II trial

cystic fibrosis phase II trial

The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
biopharmaceuticals-in-china

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
emperor-preserved-chmp-positive-opinion

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction